ClinicalTrials.gg
RecruitingNCT07180628Updated Apr 29, 2026

Organization and Development of Motor Cortical Circuits for Speech Production in Stuttering

An interventional study of Speech Production During functional magnetic resonance imaging (MRI) in Stutter, Stuttering, Adult and Stuttering, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Michigan · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The overall objective of this study is to examine inter effector areas (IEAs) activity and functional connectivity during continuous speech production in stuttering adults.

02

Conditions studied

  • Stutter
  • Stuttering, Adult
  • Stuttering
  • Stuttering, Developmental

Browse trials for

Keywords

  • Magnetic Resonance Imaging (MRI) scans
  • Behavioral assessments
03

In context

Stuttering

74 studies on the registry are indexed under Stuttering; 23 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 57 interventional studies indexed under Stuttering.

Browse Stuttering studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between the ages of 18-65 years
  • Have otherwise normal speech, language, hearing and cognition
  • Speak English as their primary language
  • Currently stutter

Exclusion criteria

Exclusion Criteria:

  • Have serious medical or neurological conditions (e.g., stroke, traumatic brain injury, Parkinson's disease, etc.)
  • Have had a closed head injury (e.g., concussion)
  • Have a reading disorder (e.g., dyslexia)
  • Have hearing loss
  • Have metal or electronic implants (e.g., cochlear implants, pacemakers, etc.)
  • Are currently pregnant
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Stutter group

    Participants that stutter

    Behavioral: Speech Production During functional magnetic resonance imaging (MRI)

Interventions

  • BehavioralSpeech Production During functional magnetic resonance imaging (MRI)

    Participants will complete a speech production task with 2 conditions (stuttered, non-stuttered) while undergoing functional MRI to assess brain activity. Brain activity will be compared within subjects for the 2 conditions. The intervention is the combination of tasks delivered to all participants. The speaking task is the intervention (modifying agent) and the MRI is a measurement tool, not a therapeutic or modifying agent.

06

What researchers measure

Primary outcomes

  1. Blood-Oxygen-Level-Dependent (BOLD) signal change during speaking

    The Blood-oxygen-level-dependent (BOLD) signal reflects changes in blood oxygenation levels that are associated with neural activity. It is measured using functional magnetic resonance imaging (fMRI) and reported in arbitrary units (a.u.). The BOLD response provides an indirect index of localized brain activity during task performance, with increased signal indicating greater activation in a given brain region relative to baseline or a comparison condition. In this study, BOLD signal differences will be compared within participants across two speech production tasks: (1) stuttered speech and (2) non-stuttered speech. Each participant will complete the speech task on several of the MRI visits, which varies per participant (total amount of time spent will be the same across participants).

    Time frame: During the speech task (5 runs, 8 minutes each) distributed across MRI Visits 1-6, up to 12 months from enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2029, 35 months after the start.

Of 37 interventional studies with no phase under Stuttering, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 18, 2025
StartActual
Apr 24, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07180628
Responsible party
Soo-Eun Chang (Associate Professor of Psychiatry, University of Michigan) — Principal investigator
First posted
Sep 18, 2025
Start date
Apr 24, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Apr 29, 2026

Study contacts

Emily Garnett, PhD
Contact
emilyog@umich.edu
734-232-3371
Soo-Eun Shang, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion